LoginRegister

    Alembic Pharma associate co gets USFDA fast track designation for cancer drug

    Written by Ruby Khatun Khatun   |  
    Alembic Pharma associate co gets USFDA fast track designation for cancer drug

    New Delhi: Drug firm Alembic Pharmaceuticals said the US health regulator has granted fast track designation to its associate company Rhizen Pharmaceuticals SA's RP6530 (tenalisib), used in the treatment of cancer.


    "The US Food and Drug Administration (USFDA) has granted Fast Track Designation for RP6530 (tenalisib)...for the treatment of patients with relapsed/refractory peripheral T- cell lymphoma (PTCL)," Alembic Pharmaceuticals said in a BSE filing.


    Fast track designation is awarded to drugs that treat a serious condition and fill an unmet medical need, it added.
    Alembic Pharmaceuticalscancercancer drugFast Track designationperipheral T- cell lymphomareceivesRhizenRhizen Pharmaceuticals SARP6530tenalisibUS Food and Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X